Hara M, Terashima Y, Kanamori S, Senga Y, Kondoh Y, Ohhara M, Tsuboi N, Nishimura T, Akimoto M
Department of Urology, Nippon Medical School.
Hinyokika Kiyo. 1988 Oct;34(10):1693-6.
Eight patients with advanced cancer of the urinary tract were treated with recombinant interleukin-2(IL-2) at our department between December, 1985 and September, 1987. Patients were given 5 x 10(5)-4 x 10(6) units of IL-2 by intravenous drip infusion daily. One of five patients who received IL-2 for over 28 days showed 62% regression in size of hepatic metastasis of bladder cancer on computed tomography and another showed marked improvement of Performance Status. The upward tendency of natural killer and lymphokine-activated killer activity of peripheral blood was observed during treatment. Fever, mental disturbance, hypotension and eosinophilia and others were recognized during administration of IL-2, and cardiac failure and disturbance of renal function were also recognized as severe side effect.
1985年12月至1987年9月期间,我科对8例晚期泌尿系统癌症患者使用重组白细胞介素-2(IL-2)进行了治疗。患者每日通过静脉滴注给予5×10⁵ - 4×10⁶单位的IL-2。在接受IL-2治疗超过28天的5例患者中,1例经计算机断层扫描显示膀胱癌肝转移灶大小缩小了62%,另1例患者的体能状态有明显改善。治疗期间观察到外周血自然杀伤细胞和淋巴因子激活的杀伤细胞活性呈上升趋势。在给予IL-2期间,出现了发热、精神障碍、低血压和嗜酸性粒细胞增多等情况,还发现心力衰竭和肾功能障碍是严重的副作用。